Delivery Order SPE2DR25D2206-SPE2DR26F9BR9
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $9,063.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) 40 mg/0.4 mL prefilled pens. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of August 5, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single...
- The Defense Logistics Agency awarded a $13,075.97 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) prefilled pens, 40 mg/0.4 mL dosage. This contract is a firm fixed price delivery order with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $19,164.60 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) 40 mg/0.4 mL prefilled pens. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 26, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary pharmaceutical distribution...
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, due for completion by June 2, 2025. The award was issued on May 30, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $37,698.62 to AmerisourceBergen Drug Corp for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic pharmaceutical used to treat autoimmune conditions. This firm fixed-price delivery order was competitively awarded without set-aside designation and has an ultimate completion date of May 21, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $17,091.36 delivery order to AmerisourceBergen Drug Corp on October 28, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This is a competitively awarded, firm fixed price contract with no set-aside designation and an ultimate completion date of October 29, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its primary pharmaceutical distribution...
- The Defense Logistics Agency awarded a $4,531.80 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) prefilled pens at 40 mg/0.4 mL. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with a completion date of July 31, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical distributor serving federal healthcare...
- The Defense Logistics Agency awarded a $4,852.12 delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for HUMIRA (adalimumab) 40 mg/0.4 mL prefilled pens. This competitively awarded, firm fixed-price contract is a non-set-aside delivery order with an ultimate completion date of November 4, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a child order under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $1,957.76 to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of HUMIRA (Adalimumab) prefilled pens at 40 mg/0.4 mL. This firm fixed-price delivery order represents a non-set-aside competitive award with an ultimate completion date of September 22, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as...
- The Defense Logistics Agency Medical Supply Chain awarded a $17,277.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens containing 40 mg/0.4 mL of pharmaceutical product. The contract, awarded on June 16, 2025, with an ultimate completion date of June 17, 2025, represents a non-competitive, non-set-aside procurement executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place of...
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9BR9Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $40,514.50 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by November 17, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor and critical vendor for federal medical procurement. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The parent contract enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. HUMIRA, a biologic treatment for rheumatoid arthritis and other inflammatory conditions, represents the type of specialty medication routinely procured through this vehicle to support active-duty service members, retirees, and beneficiaries within the Military Health System.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $40.5k | 11/14/25 |